T Cell News and Research

Latest T Cell News and Research

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

MMRGlobal, Inc. and VisiInc PLC (VZJ) have entered into an agreement to launch MMRGlobal’s patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product. Initially, the two companies will collaborate on offering products and services jointly to the health technology market in Australia, which is currently projected to be as much as $2.4 billion this year.

2 Jun 2011

Johns Hopkins researchers solve mystery of Warburg effect

It’s long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar. Many genes have been implicated in this process and now, reporting in the May 27 issue of Cell, researchers at the Johns Hopkins University School of Medicine have discovered that this so-called Warburg effect is controlled.

2 Jun 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Clovis Oncology, Inc. and Roche, announced today that they have entered into an agreement to develop an in vitro PCR based companion diagnostic test.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Cell phone use poses no cancer risk, says JunkScience publisher

Today's media hoopla about the World Health Organization classifying cell phone use as "possibly carcinogenic" is much ado about nothing. The studies the WHO relies on are weak association studies that have zero reliability.

2 Jun 2011

Researchers explore relationship between emotions and poor prognosis in heart disease

Intense distress and fear of dying, which many people experience when suffering the symptoms of a heart attack, are not only fairly common emotional responses but are also linked to biological changes that occur during the event, according to new research published online today in the European Heart Journal.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Investigators to examine how Ephb2 gene causes ependymoma in children

Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.

2 Jun 2011

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

2 Jun 2011

Researchers discover overactive genes that drive triple-negative breast cancer cells

Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Adipose-derived stem cell procedure restores skull defects after brain surgery

Stem cells derived from abdominal fat—used along with a synthetic bone grafting material—are a potentially valuable new approach to repairing skull defects after brain surgery, according to a study in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.

1 Jun 2011

Elsevier to organise third Current Opinion conference in structural biology, DNA repair

Elsevier, the leading provider of scientific, technical and medical information products and services, is organising the third Current Opinion conference, the Current Opinion in Structural Biology & DNA Repair.

1 Jun 2011

Scientists find no link between XMRV retrovirus and human disease

Delineation of the origin of the retrovirus known as XMRV from the genomes of laboratory mice indicates that the virus is unlikely to be responsible for either prostate cancer or chronic fatigue syndrome in humans, as has been widely published.

1 Jun 2011

CTI regains compliance with all applicable NASDAQ listing standards

Cell Therapeutics, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC, indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards.

1 Jun 2011

T Cell News and Research

Latest T Cell News and Research

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

Johns Hopkins researchers solve mystery of Warburg effect

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Cell phone use poses no cancer risk, says JunkScience publisher

Researchers explore relationship between emotions and poor prognosis in heart disease

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Investigators to examine how Ephb2 gene causes ependymoma in children

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Researchers discover overactive genes that drive triple-negative breast cancer cells

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Adipose-derived stem cell procedure restores skull defects after brain surgery

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Elsevier to organise third Current Opinion conference in structural biology, DNA repair

Scientists find no link between XMRV retrovirus and human disease

CTI regains compliance with all applicable NASDAQ listing standards

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in